LOGIN
Fixed-Dose Combination of Apocynin and Paeonol for Symptomatic Knee Osteoarthritis
December 2024
Fixed-Dose Combination of Apocynin and Paeonol for Symptomatic Knee Osteoarthritis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial.
Osteoarthritis Cartilage . 2024 Jul;32(7):952-962.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
A total of 152 patients with symptomatic knee osteoarthritis were randomized to receive either a combination of Apocynin and Paeonol 800 mg (APPA; n=75) or placebo (n=77) twice daily for 28 days. The primary outcome of interest was the change in pain measured using the WOMAC pain subscale. Secondary outcomes included WOMAC function and stiffness, as well as other patient-reported outcomes such as ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.